Literature DB >> 16341032

Detection of JAK2 V617F as a first intention diagnostic test for erythrocytosis.

C James, F Delhommeau, C Marzac, I Teyssandier, J-P Le Couédic, S Giraudier, L Roy, P Saulnier, L Lacroix, S Maury, M Tulliez, W Vainchenker, V Ugo, N Casadevall.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16341032     DOI： 10.1038/sj.leu.2404069

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  18 in total

1.  Concordance of assays designed for the quantification of JAK2V617F: a multicenter study.

Authors:  Eric Lippert; François Girodon; Emma Hammond; Jaroslav Jelinek; N Scott Reading; Boris Fehse; Katy Hanlon; Mirjam Hermans; Céline Richard; Sabina Swierczek; Valérie Ugo; Serge Carillo; Véronique Harrivel; Christophe Marzac; Daniela Pietra; Marta Sobas; Morgane Mounier; Marina Migeon; Sian Ellard; Nicolaus Kröger; Richard Herrmann; Josef T Prchal; Radek C Skoda; Sylvie Hermouet
Journal:  Haematologica       Date:  2008-11-10       Impact factor: 9.941

2.  Uses and abuses of JAK2 and MPL mutation tests in myeloproliferative neoplasms a paper from the 2010 William Beaumont hospital symposium on molecular pathology.

Authors:  Ayalew Tefferi; Pierre Noel; Curtis A Hanson
Journal:  J Mol Diagn       Date:  2011-06-30       Impact factor: 5.568

3.  Sensitive detection and quantification of the JAK2V617F allele by real-time PCR blocking wild-type amplification by using a peptide nucleic acid oligonucleotide.

Authors:  Cornelis J J Huijsmans; Jeroen Poodt; Paul H M Savelkoul; Mirjam H A Hermans
Journal:  J Mol Diagn       Date:  2011-06-30       Impact factor: 5.568

4.  2016 WHO Clinical Molecular and Pathological Criteria for Classification and Staging of Myeloproliferative Neoplasms (MPN) Caused by MPN Driver Mutations in the JAK2, MPL and CALR Genes in the Context of New 2016 WHO Classification: Prognostic and Therapeutic Implications.

Authors:  Jan Jacques Michiels; Mihaela Tevet; Adrian Trifa; Emilia Niculescu-Mizil; Anca Lupu; Ana Maria Vladareanu; Horia Bumbea; Anca Ilea; Camelia Dobrea; Daniela Georgescu; Oana Patrinoiu; Mihaela Popescu; Meilin Murat; Cornel Dragan; Felicia Mihai; Sabina Zurac; Silvana Angelescu; Anamaria Iova; Alina Popa; Rodica Gogulescu; Violeta Popov
Journal:  Maedica (Bucur)       Date:  2016-03

Review 5.  JAK2 V617F in myeloid disorders: molecular diagnostic techniques and their clinical utility: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology.

Authors:  David P Steensma
Journal:  J Mol Diagn       Date:  2006-09       Impact factor: 5.568

Review 6.  Genetics of myeloproliferative neoplasms.

Authors:  Aaron D Viny; Ross L Levine
Journal:  Cancer J       Date:  2014 Jan-Feb       Impact factor: 3.360

7.  JAK2 V617F and the evolving paradigm of polycythemia vera.

Authors:  Robert T Means
Journal:  Korean J Hematol       Date:  2010-06-30

8.  Detection of acquired Janus kinase 2 V617F mutation in myeloproliferative disorders by fluorescence melting curve analysis.

Authors:  N Scott Reading; Megan S Lim; Kojo S J Elenitoba-Johnson
Journal:  Mol Diagn Ther       Date:  2006       Impact factor: 4.074

9.  Melting point assay for the JAK2 V617F mutation, comparison with amplification refractory mutation system (ARMS) in diagnostic samples, and implications for daily routine.

Authors:  Sebastian Ochsenreither; Mark Reinwald; Eckhard Thiel; Thomas Burmeister
Journal:  Mol Diagn Ther       Date:  2010-06-01       Impact factor: 4.074

10.  Validation of standards for quantitative assessment of JAK2 c.1849G>T (p.V617F) allele burden analysis in clinical samples.

Authors:  Paul Collier; Keyur Patel; Paul Waeltz; Mark Rupar; Rajyalakshmi Luthra; Phillip C C Liu; Gregory Hollis; Reid Huber; Srdan Verstovsek; Timothy C Burn
Journal:  Genet Test Mol Biomarkers       Date:  2013-03-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.